Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220

Emergency: 022 - 39199100 | Ambulance: 1255 For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





(A 12 Fortis Network Hospital)

UHID	12386711	Date	01/04/20	023	
Name	Mr.Rajesh Kumar	Sex	Male	Age	45
OPD	Opthal 14	Healtl	h Check U	Jp	

	Ivame	Mr. Kajesh Kumar	SCA	Maic	Age	73
	OPD	Opthal 14	Health	Check Up)	
						L 1
Ols	No		Drug Sys	g allergy:	> No	, Kano
2004	. A. I		r	labit->	No-	
MUZ	Wo	1				
		0 1 6 6 60°	Bh	\int		
		PA - 4.78 - 4.70 AND	D~-	6/6° 50 X 15 1.50 /	50°	6(6P
		TOP > # 16.4		1.5 P	, ,	6
		Mul	R. R.	Lan Adu	× × × × × × × × × × × × × × × × × × ×	Lubra (

To Virteon Ley

Hiranandani Healthcare Pvt. Ltd.
Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703
Board Line: 022 - 39199222 | Fax: 022 - 39199220
Emergency: 022 - 39199100 | Ambulance: 1255
For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | CIN : U85100MH2005PTC154823 GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





(A 1) Fortis Network Hospital)

UHID	12386711	Date	01/04/2	023	
Name	Mr.Rajesh Kumar	Sex	Male	Age	45
OPD	Dental 12	Healtl	Check U	J p	

Drug allergy: Sys illness:





PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO: 0022WD000176

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

00176 | AGE/SEX :45 Years

DRAWN :01/04/2023 13:26:00 RECEIVED :01/04/2023 13:28:04

Male

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Final

Results

Biological Reference Interval

Units

H.	AEMATOLOGY - CBC		
CBC-5, EDTA WHOLE BLOOD		T	
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : SPECTROPHOTOMETRY	14.2	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.41 Low	4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)C	5.94 CYTOMETRY	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRICAL IMPEDANCE	225	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	41.5	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	94.2	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PAPAMETER	32.2 High	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD: CALCULATED PARAMETER	34.2	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	16.2 High	11.6 - 14.0	%
MENTZER INDEX	21.4		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	9.8	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD: FLOWCYTOMETRY	54	40 - 80	%
LYMPHOCYTES METHOD: FLOWCYTOMETRY	31	20 - 40	%

District

Dr.Akta Dubey Counsultant Pathologist



Page 1 Of 14

View Details

View Report



SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO : 0022WD000176 PATIENT ID : FH.12386711

CLIENT PATIENT ID: UID:12386711 ABHA NO

AGE/SEX :45 Years Male :01/04/2023 13:26:00 DRAWN RECEIVED : 01/04/2023 13:28:04

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
MONOCYTES METHOD: FLOWCYTOMETRY	9	2 - 10	%
EOSINOPHILS METHOD: FLOWCYTOMETRY	6	1 - 6	%
BASOPHILS METHOD: FLOWCYTOMETRY	0	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	3.21	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	1.84	1.0 - 3.0	thou/μL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.53	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.36	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT METHOD: CALCULATED PARAMETER	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD: CALCULATED PARAMETER	1.6		
MORPHOLOGY			
RBC METHOD: MICROSCOPIC EXAMINATION	PREDOMINANTLY N	ORMOCYTIC NORMOCHROMIC	
WBC METHOD: MICROSCOPIC EXAMINATION	NORMAL MORPHOL	OGY	
PLATELETS	ADEQUATE		

METHOD: MICROSCOPIC EXAMINATION

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait
(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.


Dr.Akta Dubey Counsultant Pathologist



Page 2 Of 14



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO : 0022WD000176 PATIENT ID : FH.12386711

CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX : 45 Years Male

:01/04/2023 13:26:00 DRAWN

RECEIVED : 01/04/2023 13:28:04 REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Final

Results

Biological Reference Interval

Units

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2029) 106504 This ratio element is a calculated parameter and out of NABL scope.


Dr.Akta Dubey Counsultant Pathologist



Page 3 Of 14

View Details

View Report



NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -



DRAWN



PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO : 0022WD000176

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years

:01/04/2023 13:26:00

Male

RECEIVED: 01/04/2023 13:28:04 REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD

BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Results

Biological Reference Interval Units

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

Final

18 High

0 - 14

mm at 1 hr

METHOD: WESTERGREN METHOD

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:
ErYTHROCYTE SEDIMENTATION RATE (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; It is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue Injury, Pregnancy, Estrogen medication, Aging.

Estroyen medicator, rights, plant of the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr.Akta Dubey Counsultant Pathologist



Page 4 Of 14

View Report



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MR.RAJESH KUMAR

ACCESSION NO : 0022WD000176 CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

PATIENT ID : FH.12386711

CLIENT PATIENT ID: UID:12386711

ABHA NO

REF. DOCTOR : SELF AGE/SEX

Male ·45 Years

DRAWN :01/04/2023 13:26:00 RECEIVED : 01/04/2023 13:28:04

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Final

Results

Biological Reference Interval

Units

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

RH TYPE

TYPE AB

METHOD: TUBE AGGLUTINATION

POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Page 5 Of 14

Dr.Akta Dubev **Counsultant Pathologist**







SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001 ACCESSION NO : 0022WD000176

REF. DOCTOR : SELF

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years Male DRAWN :01/04/2023 13:26:00

RECEIVED :01/04/2023 13:28:04 REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION :

UID:12386711 REQNO-1454759 CORP-OPD

BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status Final Results Biological Reference Interval Units

	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.66	0.2 - 1.0	mg/dL
METHOD: JENDRASSIK AND GROFF BILIRUBIN, DIRECT	0.10	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER	0.56	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: BIURET	7.2	6.4 - 8.2	g/dL
ALBUMIN METHOD: BCP DYE BINDING	3.9	3.4 - 5.0	g/dL
GLOBULIN METHOD: CALCULATED PARAMETER	3.3	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.2	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV WITH PSP	18	15 - 37	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITH P5P	34	< 45.0	U/L
ALKALINE PHOSPHATASE METHOD: PNPP-ANP	115	30 - 120	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	45	15 - 85	U/L
LACTATE DEHYDROGENASE METHOD: LACTATE - PYRUVATE	146	100 - 190	U/L
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD: HEXOKINASE	83	74 - 99	mg/dL

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

Quart

Dr.Akta Dubey Counsultant Pathologist



Page 6 Of 14

View Details

View Report



SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel : 022-39199222,022-49723322,
CIN - U7-4899PB1995PLC045956
Email : -





REF. DOCTOR : SELF



PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO: 0022WD000176

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years DRAWN

:01/04/2023 13:26:00 RECEIVED : 01/04/2023 13:28:04

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

BILLNO-150123OPCR019165					
Test Report Status <u>Final</u>	Results		Biological Reference Inter	val Units	
HBA1C	5.2		Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)	%	
METHOD: HB VARIANT (HPLC)			< 116.0	mg/dL	
ESTIMATED AVERAGE GLUCOSE(EAG) METHOD: CALCULATED PARAMETER	102.5		< 116.0	mg/uL	
KIDNEY PANEL - 1					
BLOOD UREA NITROGEN (BUN), SERUM					
BLOOD UREA NITROGEN METHOD: UREASE - UV	7		6 - 20	mg/dL	
CREATININE EGFR- EPI					
CREATININE METHOD: ALKALINE PICRATE KINETIC JAFFES	0.77 Low		0.90 - 1.30	mg/dL	
AGE	45			years	
GLOMERULAR FILTRATION RATE (MALE) METHOD: CALCULATED PARAMETER	112.51		Refer Interpretation Below	mL/min/1.73m2	
BUN/CREAT RATIO					
BUN/CREAT RATIO METHOD: CALCULATED PARAMETER	9.09		5.00 - 15.00		
URIC ACID, SERUM					
URIC ACID METHOD: URICASE UV	6.7		3.5 - 7.2	mg/dL	
TOTAL PROTEIN, SERUM					
TOTAL PROTEIN METHOD: BTURET	7.2		6.4 - 8.2	g/dL	
ALBUMIN, SERUM					
ALBUMIN METHOD: BCP DYE BINDING	3.9		3.4 - 5.0	g/dL	

GLOBULIN

Dr.Akta Dubey **Counsultant Pathologist**





Page 7 Of 14



SRL Ltd HIRAMANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956





AGE/SEX



Male

PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

ACCESSION NO : 0022WD000176

REF. DOCTOR : SELF

PATIENT ID : FH.12386711

CLIENT PATIENT ID: UID:12386711

ABHA NO

:01/04/2023 13:26:00 DRAWN RECEIVED: 01/04/2023 13:28:04

:45 Years

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759

CORP-OPD

BILLNO-1501230PCR019165

BILLNO-1501230PCK019165				
Test Report Status Final	Results	Biological Referenc	e Interval Units	
GLOBULIN	3.3	2.0 - 4.1	g/dL	
METHOD: CALCULATED PARAMETER ELECTROLYTES (NA/K/CL), SERUM				
SODIUM, SERUM METHOD: ISE INDIRECT	138	136 - 145	mmol/L	
POTASSIUM, SERUM METHOD: ISE INDIRECT	4.52	3.50 - 5.10	mmol/L	
CHLORIDE, SERUM METHOD: ISE INDIRECT	102	98 - 107	mmol/L	
Interpretation(s)				

Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

LIVER FUNCTION PROFILE
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give
yellow discoloration in jaundice.

Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropolesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and
abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis,
Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the
bile ducts like in Gallstones getting into the bile ducts, tumors a Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or
perinicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to
bilirubin.

bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatorislular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliery obstruction, Osteoblastic bone tumors, osteomalada, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tussues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive liver diseases.

index of liver dystruction. Elevated serum GG1 activity can be round in diseases of one liver, filliarly system and pancreas. Conductors that increase serum GG1 activity can be round in diseases of one liver, filliarly system and pancreas. Conductors that increase serum GG1 are obstitutive liver diseases, high accordance or that increase serum GG1 are obstitutive liver diseases. Conductors in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels

Dr.Akta Dubev Counsultant Pathologist





Page 8 Of 14

View Report



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -







PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO : 0022WD000176

REF. DOCTOR : SELF

PATTENT ID : FH 12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years DRAWN

:01/04/2023 13:26:00 RECEIVED: 01/04/2023 13:28:04

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD

BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Results

Biological Reference Interval

Units

Test Report Status

Final

(hyposibuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodillution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothet no glucose is excreted in the urine.

urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids phenytoin, estrogen, thiazides.

Decreased in:Pancreatic Islet cell disease with increased insulin insulinoma, adrenocortical insulficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibrosarcoma), Infant of a diabetic mother, enzyme deficiency diseases(e.g.galactosemia), Drugs-insulin, ethanol, proprenolol; sulfonylureas, talbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Penal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1. Evaluating the long-term control of block glucose content above in clearly powers.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times 2 t

- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbillrubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
 BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,
 Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostalism)
 Causes of decreased level include Liver disease, SIADH.
 CREATERING ECER. BLUCSD. Chargedor (Highlips and (GER) is a measure of the function of the kidneys. The GER is a calculation based on a serum creations test.

CREATININE EGFR-EPI-GFR—Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test.

Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range, A GFR below 60 may mean kidney disease. A GFR of 15 or lower may mean kidney failure.

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation, especially in patients with higher GFR. This results in reduced misclassification of CKD.

The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Dedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sciences

TOTAL PROTEIN, SERUM-Is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, Including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Dr.Akta Dubey Counsultant Pathologist



View Report

Page 9 Of 14

PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -





REF. DOCTOR : SELF



PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

Final

ACCESSION NO : 0022WD000176

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

Results

AGE/SEX : 45 Years DRAWN

Male :01/04/2023 13:26:00

RECEIVED : 01/04/2023 13:28:04 REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Biological Reference Interval Units

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, mainutrition and wasting etc.

Dr.Akta Dubev **Counsultant Pathologist**



Page 10 Of 14



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

ACCESSION NO : 0022WD000176

REF. DOCTOR : SELF

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years DRAWN

:01/04/2023 13:26:00 RECEIVED : 01/04/2023 13:28:04

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD

BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Final

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

Results

Biological Reference Interval

Units

BIOCHEMISTRY - LIPID

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL

210 High

101

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

mg/dL

< 150 Normal 150 - 199 Borderline High

200 - 499 High

>/=500 Very High

METHOD: ENZYMATIC ASSAY

HDL CHOLESTEROL

TRIGLYCERIDES

39 Low

< 40 Low >/=60 High mg/dL

METHOD: DIRECT MEASURE - PEG

LDL CHOLESTEROL, DIRECT

148 High

< 100 Optimal

mg/dL

100 - 129 Near or above optimal 130 - 159 Borderline High

160 - 189 High >/= 190 Very High

METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

NON HDL CHOLESTEROL

171 High

Desirable: Less than 130

mg/dL

Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219 Very high: > or = 220

METHOD: CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED PARAMETER

20.2

</= 30.0

mg/dL

CHOL/HDL RATIO

5.4 High

3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk

> 11.0 High Risk

METHOD: CALCULATED PARAMETER

LDL/HDL RATIO

3.8 High

0.5 - 3.0 Desirable/Low Risk

3.1 - 6.0 Borderline/Moderate Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER

Dr.Akta Dubev Counsultant Pathologist



Page 11 Of 14

PERFORMED AT :

Email: -

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

Final

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO : 0022WD000176

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years Male DRAWN :01/04/2023 13:26:00

RECEIVED: 01/04/2023 13:28:04 REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD

BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Results

Biological Reference Interval Units

Interpretation(s)

Dr.Akta Dubey Counsultant Pathologist



Page 12 Of 14

View Details

View Report



PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, MAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



AGE/SEX

REF. DOCTOR : SELF



PATIENT NAME: MR.RAJESH KUMAR

ACCESSION NO: 0022WD000176

CODE/NAME & ADDRESS : C000045507 - FORTIS FORTIS VASHI-CHC -SPLZD

FORTIS HOSPITAL # VASHI,

MUMBAI 440001

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

DRAWN :01/04/2023 13:26:00 RECEIVED :01/04/2023 13:28:04

:45 Years

REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759

CORP-OPD

BILLNO-1501230PCR019165

BILLNO-1501230PCR019165

Test Report Status Final

Results

Biological Reference Interval

Units

CLINICAL PATH - URINALYSIS

KIDNEY PANEL - 1

PHYSICAL EXAMINATION, URINE

COLOR

PALE YELLOW

METHOD : PHYSICAL

APPEARANCE

CLEAR

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

PH

7.0

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD

SPECIFIC GRAVITY

<=1.005

1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

PROTEIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

GLUCOSE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

KETONES

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HARMOGLOBIN

BUIRUBIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

UROBILINOGEN

NORMAL

NORMAL

METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRATE

NOT DETECTED

NOT DETECTED

LEUKOCYTE ESTERASE NOT DET METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

Didny.

Dr.Akta Dubey Counsultant Pathologist Rikhe. N

Dr. Rekha Nair, MD Microbiologist



View Details

View Report

Page 13 Of 14

PERFORMED AT:

Email: -

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956





REF. DOCTOR : SELF



PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001 ACCESSION NO: 0022WD000176

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years Male

DRAWN :01/04/2023 13:26:00 RECEIVED :01/04/2023 13:28:04 REPORTED :01/04/2023 14:59:05

CLINICAL INFORMATION :

UID:12386711 REQNO-1454759

CORP-OPD

BILLNO-1501230PCR019165

BILLNO-1501230PCR019165	Results	Biological Reference Interval Units	
Test Report Status Final	Resulto		
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION CASTS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
CRYSTALS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
YEAST METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	THE CONTRACTOR
REMARKS	URINARY MICROSCO CENTRIFUGED SEDIM	PIC EXAMINATION DONE C ENT.	IN UKINAKY
Interpretation(s)			

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

District

Dr.Akta Dubey Counsultant Pathologist Rikha. N


Dr. Rekha Nair, MD Microbiologist Page 14 Of 14





View Details

View Report



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956





REF. DOCTOR : SELF



PATIENT NAME: MR.RAJESH KUMAR

ACCESSION NO : 0022WD000176

CODE/NAME & ADDRESS : C000045507 - FORTIS FORTIS VASHI-CHC -SPLZD

PATIENT ID : FH.12386711

FORTIS HOSPITAL # VASHI, MUMBAI 440001

CLIENT PATIENT ID: UID:12386711

ABHA NO

AGE/SEX :45 Years Male
DRAWN :01/04/2023 13:26:00

RECEIVED : 01/04/2023 13:28:04 REPORTED : 01/04/2023 18:17:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

ro

145.50

80 - 200

ng/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

TA

9.79

5.1 - 14.1

μg/dL

METHOD : ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

TSH (ULTRASENSITIVE)

3.830

0.270 - 4.200

µIU/mL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

Interpretation(s)

Page 1 Of 2



Dr. Swapnil Sirmukaddam Consultant Pathologist





View Details

View Report

PERFORMED AT :

SRL Ltd BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115, CIN - U74899PB1995PLC045956







PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO: 0022WD000176

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ABHA NO

REF. DOCTOR : SELF AGE/SEX :45 Years

DRAWN

Male :01/04/2023 13:26:00

RECEIVED : 01/04/2023 13:28:04 REPORTED :01/04/2023 18:17:05

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759

CORP-OPD

BILLNO-1501230PCR019165

BILLNO-1501230PCR019165

Test Report Status

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN

0.674

< 20

ng/mL

METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

Final

Interpretation(s)
PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis.
- PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the

- PSA is not detected of detected at very low levels) in the patients product of the patient.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

- Serial PSA levels can help determine the success of prostatectorry and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benigh Prostatic Hyperplacia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA.

(faise positive) levels persisting up to 3 weeks.

- As per American unological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years, Following Age specific reference

range can be used as a guide lines-

Age of male Reference range (ng/ml) 40-49 years 0-2.5 50-59 years 0-3.5 60-69 years 0-4.5

70-79 years 0-6.5

(* conventional reference level (< 4 ng/ml) is already mentioned in report, which covers all agegroup with 95% prediction interval)
PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical
interpretations. Recommended follow up on same platform as patient result can vary due to differences in assay method and reagent specificity.

References- Teitz , textbook of clinical chemistry, 4th edition) 2. Wallach's Interpretation of Diagnostic Tests

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam Consultant Pathologist

CIN - U74899PB1995PLC045956





Page 2 Of 2



SRL Ltd BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,

劉邦短別劉剛 Patient Ref. No. 22000000838193



DRAWN



PATIENT NAME: MR.RAJESH KUMAR

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO : 0022WD000236

PATIENT ID : FH.12386711 CLIENT PATIENT ID: UID:12386711

ARHA NO

AGE/SEX :45 Years

:01/04/2023 15:32:00

RECEIVED: 01/04/2023 15:32:10 REPORTED :01/04/2023 16:49:33

CLINICAL INFORMATION:

UID:12386711 REQNO-1454759 CORP-OPD BILLNO-1501230PCR019165 BILLNO-1501230PCR019165

Test Report Status

METHOD : HEXOKINASE

Final

Results

Biological Reference Interval

Units

BIOCHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

118

70 - 139

mg/dL

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr.Akta Dubey Counsultant Pathologist

Page 1 Of 1

PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -



Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D

(For Billing/Reports & Discharge Summary only)





DEPARTMENT OF NIC

Date: 03/Apr/2023

Name: Mr. Rajesh Kumar Age | Sex: 45 YEAR(S) | Male

Order Station : FO-OPD

Bed Name :

UHID | Episode No : 12386711 | 19277/23/1501 Order No | Order Date: 1501/PN/OP/2304/40475 | 01-Apr-2023 Admitted On | Reporting Date : 03-Apr-2023 17:23:30

Order Doctor Name : Dr.SELF.

TREAD MILL TEST (TMT)

Resting Heart rate	87 bpm	
Resting Blood pressure	120/80 mmHg	
Medication	Nil	
Supine ECG	Normal	
Standard protocol	BRUCE	
Total Exercise time	07 min 15 seconds	
Maximum heart rate 173 bpm		
Maximum blood pressure	150/80 mmHg	
Workload achieved	8.9 METS	
Reason for termination	Target heart rate achieved	

Final Impression:

STRESS TEST IS NEGATIVE FOR EXERCISE INDUCED MYOCARDIAL ISCHEMIA AT 8.9 METS AND 98 % OF MAXIMUM PREDICTED HEART RATE.

DR.PRASHANT PAWAR, DNB(MED),DNB(CARDIOLOGY)